Loading clinical trials...
Loading clinical trials...
Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent yea...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Wills Eye
Collaborators
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT04959097 · Retinoblastoma, Retinoblastoma Bilateral, and more
NCT06679634 · Retinoblastoma
NCT03267459 · Retinoblastoma
NCT06424301 · Retinoblastoma, Refractory
Oncology Service, Wills Eye Institute
Philadelphia, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions